ArticleThe American journal of pathology2002
Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 95 citations in OpenAlex.
- Immune regulation by CD55 in chronic beryllium disease.American journal of respiratory cell and molecular biology · 2026Article
- CD55-expressing myeloid-derived suppressor cells (MDSCs) drive cancer immunoevasion.Journal for immunotherapy of cancer · 2026Article
- Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.The Journal of clinical investigation · 2025Review
- Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.Journal of leukocyte biology · 2024Review
- CD8Nature communications · 2023Article
- Genomic biomarkers in chronic beryllium disease and sarcoidosis.Respiratory medicine · 2021Article
- Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology.PLoS pathogens · 2021Article
- Limited Effect of Indolamine 2,3-Dioxygenase Expression and Enzymatic Activity on Lupus-Like Disease in B6.Nba2 Mice.Frontiers in immunology · 2019Article
- Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.Molecular and cellular biochemistry · 2016Article
- Complement in Lupus Nephritis: New Perspectives.Kidney diseases (Basel, Switzerland) · 2015Review
- The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Lupus Nephritis: Animal Modeling of a Complex Disease Syndrome Pathology.Drug discovery today. Disease models · 2014Article
- Decay-accelerating factor 1 deficiency exacerbates leptospiral-induced murine chronic nephritis and renal fibrosis.PloS one · 2014Article
- Article
- A tandem repeat in decay accelerating factor 1 is associated with severity of murine mercury-induced autoimmunity.Autoimmune diseases · 2014Article
- The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.Autoimmune diseases · 2014Review
- Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease.Immunology · 2012Article
- Early and extensive CD55 loss from red blood cells supports a causal role in malarial anaemia.Malaria journal · 2011Article
- Finding Balance: T cell Regulatory Receptor Expression during Aging.Aging and disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Decay-accelerating factor (DAF, CD55) is a glycosylphosphatidylinositol-anchored membrane protein that restricts complement activation on autologous cells. It is also a ligand for CD97, an activation-associated lymphocyte antigen with seven transmembrane domains. It is widely expressed on cells of both the hematopoietic and nonhematopoietic lineages. Although deficiency of DAF on human erythrocytes is associated with the hemolytic anemia syndrome paroxysmal nocturnal hemoglobinuria, the in vivo biology of DAF is still poorly understood. We addressed the in vivo function of DAF in a knockout mouse model and describe here that deletion of DAF exacerbates autoimmune disease development in MRL/lpr mice, a model for human systemic lupus erythematosus. Compared to DAF-sufficient littermate controls, DAF-deficient female MRL/lpr mice developed exacerbated lymphadenopathy and splenomegaly, higher serum anti-chromatin autoantibody levels, and aggravated dermatitis. Consistent with the phenotype of aggravated dermatitis in DAF-deficient mice, Northern and Western blots and immunofluorescence studies showed DAF to be expressed abundantly in the mouse skin, suggesting that it may play a particularly important role in this tissue. Histology and immunostaining demonstrated inflammatory infiltrate and focal C3 deposition in early skin lesions, mostly along the dermal-epidermal junction. These results reveal a protective function of DAF in the development of a systemic autoimmune syndrome and suggest that dysfunction or down-regulation of DAF may contribute to autoimmune disease pathogenesis and manifestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.